Exforge
Product Images NDC 54868-5804

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Exforge (NDC 54868-5804). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – Package Label – 10 mg*/160 mg Tablets (5804)

Label for Exforge 10/160 mg by Physicians Total Care, Inc., distributed in Tulsa, OK. The label includes the NDC 54868-5004-0, lot number, expiration date 01/60, and states manufacturing by Novartis Pharma Stein AG, Stein, Switzerland. A barcode with the number 58040300000 is also shown.*

FDA Label Image

Principal Display Panel – Package Label – 10 mg*/320 mg Tablets (5983)

Exforge 10 mg/320 mg tablets packaging label from Physicians Total Care, Inc. The label shows the proprietary name Exforge with its active ingredients amlodipine and valsartan. The strength is 10 mg/320 mg, and the package contains 90 tablets. It includes warnings against use without prescription, lot number, expiration date, and storage conditions.*

FDA Label Image

Principal Display Panel – Package Label – 5 mg*/320 mg Tablets (5996)

Exforge 5 mg/320 mg tablets packaging label from Physicians Total Care, Inc. The label includes the generic names amlodipine and valsartan, with a quantity of 90 tablets. It provides directions to use once daily and includes storage and caution information along with lot and expiry dates.*

FDA Label Image

Principal Display Panel – Package Label – 5 mg*/160 mg Tablets (5997)

Exforge 5mg/160mg tablets package label by Physicians Total Care, Inc. The label indicates the product contains Amlodipine and Valsartan, with a quantity of 90 tablets. The label includes warning and storage information as well as lot and expiration details.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Exforge 01)

A line graph comparing the percentage of patients achieving systolic blood pressure (SBP) below 140 mmHg at baseline SBP values from 140 to 180 mmHg. The graph shows four treatments: Exforge 10/320 mg, Valsartan 320 mg, Amlodipine 10 mg, and Placebo, each represented by different markers. The vertical axis represents % SBP <140 mmHg, and the horizontal axis shows baseline SBP (mmHg).*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Exforge 02)

A line graph comparing the percentage reduction in sitting systolic blood pressure (SBP) versus baseline diastolic blood pressure (DBP) for four groups: Exforge (10/320 mg), Valsartan 320 mg, Amlodipine 10 mg, and Placebo. Data points show the trend of SBP changes across a range of baseline DBP values from 95 to 110 mmHg, with Exforge showing the greatest reduction and Placebo the least.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Exforge 03)

A line graph comparing the percentage of subjects with systolic blood pressure (SBP) below 140 mm Hg versus baseline SBP for four treatments: Exforge 10/320 mg, Valsartan 320 mg, Amlodipine 10 mg, and Placebo. The x-axis represents baseline SBP (mm Hg) from 140 to 180, and the y-axis shows the percentage of subjects achieving SBP less than 140 mm Hg.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Exforge 04)

A line graph comparing the percentage reduction in estimated blood pressure (% EBP) against baseline diastolic blood pressure (DBP) for Exforge 10/320 mg, valsartan 320 mg, amlodipine 10 mg, and placebo. The graph shows treatment response trends relative to baseline DBP values from 85 to 110 mmHg.*

FDA Label Image

Amlodipine Besylate Structural Formula (Exforge 05)

Chemical structure of the active ingredient(s) in Exforge, showing multiple aromatic rings with chlorine, methoxy, carboxylate, sulfonic acid groups, and an extended amine chain. The diagram depicts molecular connectivity and functional groups relevant to the compound.*

FDA Label Image

Valsartan Structural Formula (Exforge 06)

Chemical structure diagram showing the molecular formula of an active ingredient, featuring a complex arrangement of carbon, nitrogen, oxygen atoms, and functional groups typical for pharmaceutical compounds in Exforge.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.